

Maria Roussou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10838456/publications.pdf>

Version: 2024-02-01

81
papers

2,040
citations

304743

22
h-index

254184

43
g-index

81
all docs

81
docs citations

81
times ranked

2321
citing authors

#	ARTICLE	IF	CITATIONS
1	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3088.	2.4	2
2	Chromosome 1q21 aberrations identify ultra-high-risk myeloma with prognostic and clinical implications. <i>American Journal of Hematology</i> , 2022, 97, 1142-1149.	4.1	10
3	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 19-23.	3.0	22
4	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 3-11.	3.0	18
5	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2021, 193, 113-118.	2.5	15
6	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. <i>Leukemia</i> , 2021, 35, 1418-1427.	7.2	15
7	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	6.2	103
8	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 259-266.	3.0	8
9	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3201.	2.4	1
10	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. <i>Leukemia and Lymphoma</i> , 2020, 61, 3247-3250.	1.3	3
11	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 109.	6.2	21
12	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.	1.8	9
13	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 25.	6.2	16
14	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020, 4, e381.	2.7	14
15	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 103-110.	3.0	11
16	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.4	23
17	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020, 95, E148-E150.	4.1	12
18	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	1.8	17

#	ARTICLE	IF	CITATIONS
19	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	6.2	15
20	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020, 136, 12-12.	1.4	0
21	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. <i>Blood</i> , 2020, 136, 48-49.	1.4	7
22	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 25-25.	1.4	1
23	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. <i>Blood</i> , 2020, 136, 21-21.	1.4	4
24	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019, 125, 744-758.	4.5	22
25	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	1.8	9
26	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.	4.1	11
27	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.2	17
28	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	5.2	37
29	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 23-28.	0.4	2
30	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	4.1	21
31	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	1.3	9
32	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2019, 134, 1877-1877.	1.4	0
33	Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 1894-1894.	1.4	1
34	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.	1.4	44
35	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	1.4	54
36	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2018, 59, 983-987.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	3.0	24
38	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 46.	6.2	39
39	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	7.2	40
40	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. <i>Blood</i> , 2018, 132, 1966-1966.	1.4	3
41	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018, 132, 3247-3247.	1.4	0
42	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2304-2309.	1.3	17
43	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.	4.1	48
44	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017, 102, 593-599.	3.5	72
45	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017, 58, 1832-1839.	1.3	24
46	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1506-1508.	1.3	9
47	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017, 1, 449-454.	5.2	89
48	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016, 91, 499-502.	4.1	73
49	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1776-1780.	1.3	3
50	Neutrophil Gelatinase-Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 29-35.	0.4	16
51	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. <i>Blood</i> , 2016, 128, 4500-4500.	1.4	0
52	Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. <i>American Journal of Hematology</i> , 2015, 90, E60-5.	4.1	55
53	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. <i>Blood</i> , 2014, 124, 306-306.	1.4	4
54	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. <i>Blood</i> , 2014, 124, 4738-4738.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014, 124, 4769-4769.	1.4	1
56	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. <i>Blood</i> , 2014, 124, 2028-2028.	1.4	0
57	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2014, 124, 2029-2029.	1.4	0
58	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3462-3462.	1.4	0
59	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. <i>Blood</i> , 2014, 124, 3464-3464.	1.4	0
60	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. <i>Blood</i> , 2014, 124, 2130-2130.	1.4	0
61	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenström's Macroglobulinemia. <i>Blood</i> , 2013, 122, 1860-1860.	1.4	2
62	The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). <i>Blood</i> , 2013, 122, 3196-3196.	1.4	1
63	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. <i>Blood</i> , 2013, 122, 1867-1867.	1.4	1
64	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. <i>Blood</i> , 2012, 119, 5384-5390.	1.4	88
65	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. <i>American Journal of Hematology</i> , 2012, 87, 861-864.	4.1	81
66	Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. <i>Leukemia and Lymphoma</i> , 2011, 52, 2299-2303.	1.3	28
67	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884.	4.1	16
68	High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. <i>European Journal of Haematology</i> , 2010, 85, 114-119.	2.2	113
69	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. <i>Leukemia Research</i> , 2010, 34, 1395-1397.	0.8	64
70	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 302-306.	1.4	101
71	Wegener's Granulomatosis Presenting as a Renal Mass. <i>Urology</i> , 2008, 71, 547.e1-547.e2.	1.0	20
72	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2008, 49, 890-895.	1.3	74

#	ARTICLE	IF	CITATIONS
73	Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. <i>Haematologica</i> , 2007, 92, 546-549.	3.5	160
74	Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. <i>Haematologica</i> , 2007, 92, 1351-1358.	3.5	179
75	Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.. <i>Blood</i> , 2007, 110, 191-191.	1.4	1
76	Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.. <i>Blood</i> , 2007, 110, 2739-2739.	1.4	2
77	Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures.. <i>Blood</i> , 2007, 110, 3609-3609.	1.4	3
78	Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.. <i>Blood</i> , 2007, 110, 4812-4812.	1.4	0
79	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1 α and Angiogenic Cytokines.. <i>Blood</i> , 2006, 108, 3541-3541.	1.4	8
80	Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2006, 108, 3095-3095.	1.4	0
81	Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5018-5018.	1.4	0